ATRA - Atara Biotherapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ATRA

ATARA BIOTHERAPEUTICS, INC.

NASDAQ

$9.20

▼ DOWN 0.54% (-0.05)

KEY STATISTICS

Market Cap$82.89 M

52w High$19.14

52w Low$3.92

Dividend Yield—

Frequency—

P/E-13.73

Volume15.35K

Shares Out.9.01M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Anhco Nguyen

COMPENSATION 2026

Salary$585,769

Stock Awards$781,650

Incentive Plan Pay$145,808

All Other Comp.$8,943

Total$1,573,716

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 16, 2014

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$13.00

Target Low$13.00

Target Median$13.00

Target Consensus$13.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$1.00M

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2024-06-20	Reverse	1:25

PRICE

$9.20 ▼ DOWN 0.54% (−$0.05)

OVERLAYS

About Atara Biotherapeutics, Inc.

https://www.atarabio.com ↗

Atara Biotherapeutics develops off-the-shelf T-cell immunotherapies for cancer, autoimmune, and viral diseases, including tabelecleucel for EBV-related conditions and next-gen CAR T therapies for hematologic and solid tumors.

INDUSTRY

Biotechnology

A PRODUCT ATARA BIOTHERAPEUTICS, INC. IS KNOWN FOR

EBVALLO™ (tabelecleucel)

EBVALLO™ is an investigational allogeneic T-cell therapy for EBV+ post-transplant lymphoproliferative disease, and despite a recent FDA Complete Response Letter, it remains Atara's leading off-the-shelf immunotherapy candidate.